Drug intelligence / Profile preview

FX-9847

Development stage: Preclinical
Lead developer: Felicitex Therapeutics
Modality: Small Molecules
Administration: Intraperitoneal

Overview

FX-9847 is a preclinical small molecule inhibitor developed by Felicitex Therapeutics, specifically designed to target the EGFR T790M mutation in non-small cell lung cancer (NSCLC). Its unique mechanism of action involves selectively disrupting dormant cancer cells by inhibiting their ability to enter or maintain a quiescent state. By preventing dormancy, the compound forces cancer cells to accumulate lethal DNA damage, offering a potential strategy to eliminate resistant cell populations that typically survive standard therapies and contribute to disease recurrence.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)DYRK1B (Dual specificity tyrosine-phosphorylation-regulated kinase 1B)

Beyond the preview

Go deeper on FX-9847.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FX-9847.

Explore the full profile